Amarin Corporation PLC (AMRN) stock prices were up by 3.12% as of the market closing on September 22nd, 2021. This brought the price per share up to USD$5.29 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 2.08%, bringing it up to USD$5.40.
AMRN Stock’s New Strategy
September 22nd, 2021 saw AMRN stock outline its new Go-to-Market strategy to accelerate the growth of VASCEPA in the United States. The strategy focuses on the expansion of healthcare professional engagement via a new omnichannel platform. This will enhance managed care access and optimize VASCEPA prescriptions for cardiovascular (CV) risk reduction.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Expansion of VASCEPA
AMRN stock’s strategy is set to be transformative, serving to further its mission of helping the vast demographic of untreated, at-risk patients. The company has reported seeing a substantial shift in how physicians prefer to engage with both healthcare professionals and patients. This is in addition to the application of key learnings from the company’s European launch initiatives in a bid to maximize its impact. The company is keen to capitalize on the massive opportunity for VASCEPA/VAZKEPA in the United States and abroad. The new strategy is believed to drive U.S growth as the company realizes the full potential of its first-of-its-kind product.
AMRN Stock’s Patient Focus
AMRN stock will continue collaborating with payers to enhance its strong managed care position. These efforts will also facilitate the removal of barriers to VASCEPA prescriptions. This will ensure that patients in need of CV risk reduction receive proper therapy. Furthermore, the company’s large Commercial and Medicare Part D payers currently cover VASCEPA as the exclusive IPE product on account of its cost effectiveness.
Scope of VASCEPA
Currently, branded VASCEPA is the only available IPE medication that has been approved by the U.S Food and Drug Administration. The company is continuing to aggressively educate critical stakeholders in the prescribing continuum to prevent improper generic substitution for the indication. This will ensure proper fulfillment of the treatment at each stage of treatment. Furthermore, AMRN stock is evaluating various innovative solutions that are designed to better manage IPE prescriptions for CV risk reduction.
Future Outlook for AMRN Stock
AMRN stock is keen to capitalize on the opportunities presented to it as a result of its new strategy. The company is setting the stage to accelerate the development and proliferation of its VASCEPA treatment. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate sustained and significant increases in shareholder value over the long term.
